Filing Flows › Aytu Biopharma (AYTU) › Q2 FY26
Aytu Biopharma (AYTU) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Feb 3, 2026
Aytu Biopharma (AYTU) reported revenue of $15.2M for the second quarter fiscal 2026 (Q2 FY26), -7% from a year earlier and +9% from the quarter before. Operating margin was -13.0%, net loss $10.6M (69.8% of revenue).
Aytu Biopharma, Q2 FY26: revenue $15.2M (-6% year over year), operating margin -13.0%, net loss $10.6M, operating cash flow $3.7M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.2M | +9% | -7% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$10.6M | -639% | -1443% |
| Operating cash flow | $3.7M | — | +27% |
| Free cash flow | $3.7M | — | +26% |
What changed
Revenue was $15.2M in Q2 FY26, down 7% year over year and up 9% from the previous quarter.
Gross margin was 63.5%, down 3.0 points from Q2 FY25. Operating costs exceeded revenue by $2.0M, an operating margin of -13.0%. Operating expenses fell 7% while revenue fell 7%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $10.6M, after a profit of $2.0M the previous quarter. Net interest and other expense of $8.6M was the main reason.
Operating cash flow was $3.7M (up 27% year over year). Non-cash charges added back $885K of depreciation and amortization and $283K of share-based compensation. Working capital and other items added $13.1M. Capital expenditures of $17K left free cash flow of $3.7M.
Questions
What was Aytu Biopharma's revenue in the second quarter fiscal 2026?
Aytu Biopharma (AYTU) reported revenue of $15.2M for the second quarter fiscal 2026 (Q2 FY26), -7% from a year earlier and +9% from the quarter before.
Was Aytu Biopharma profitable in the second quarter fiscal 2026?
Operating loss was $2.0M (-13.0% of revenue) and net loss $10.6M.
Source: Aytu Biopharma 10-Q on SEC EDGAR.